Search Results 151-160 of 37367 for Two-phase

1. New treatment option for early type 1 diabetes - Mayo Clinic

   ... stages: Stage 1: two or more positive diabetes autoantibodies but normal blood glucose levels. Stage 2: two or more positive diabetes autoantibodies and ...

2. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...

3. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

   About this study. The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), ...

4. Lymphoma - Stages - Mayo Clinic

   At stage 1, lymphoma affects only one lymph node region or one site outside of the lymph nodes. Stage 2 lymphoma. A stage 2 lymphoma involves two or more lymph ...

5. A Phase 2 Trial Of ALN-APP In Patients With Cerebral Amyloid Angiopathy - Mayo Clinic

   The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated ...

6. A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

7. A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease - Mayo Clinic

   A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in ...

8. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

9. Phase 2 Study of JK07 in Chronic Heart Failure - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

10. Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) - Mayo Clinic

    PSSc-001 (LOTUSS) This study is a Phase 2, multinational, open-label ... two or more of the minor criteria, i.e., 1) sclerodactyly, 2) digital pitting ...